{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:05:36Z","timestamp":1791198336202,"version":"4.1.0"},"reference-count":34,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To examine beneficial or detrimental effects of protease inhibitor (PI)-containing antiretroviral regimens on height and weight growth in children with human immunodeficiency virus (HIV) infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A prospective cohort study was conducted of 906 HIV-infected children, from pediatric research clinics in the United States, who were between 3 months and 18 years of age and who had height and weight assessed in 1995 (before introduction of PIs in this population) and at least once more through 1999. Changes in age- and gender-adjusted height and weight growth associated with PI use were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Compared with a healthy reference population, children were more affected in height (mean z score: \u22120.90 [18th percentile]) than in weight (mean zscore: \u22120.42 [34th percentile]) at baseline (1995). Two thirds of children received at least 1 PI during 1996 to 1999. In the multivariate mixed effects regression models adjusted for baseline log10 CD4 cell count, baseline age, gender, and race\/ethnicity, the use of PIs was associated with per-year gains of 0.13 z scores in height and 0.05 z scores in weight relative to the expected growth with non\u2013PI-containing regimens (eg, after 1 year of PI use, a representative 6-year-old boy in our study would be approximately 0.7 cm taller and 0.1 kg heavier than if he had not received PIs). No significant differential effects of PIs on height or weight growth according to specific agents or children's sociodemographic or clinical characteristics were found.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions.<\/jats:title><jats:p>Although the use of PI-containing regimens was not associated with growth retardation, it was associated with only small annual increments in height and weight growth in HIV-infected children.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.108.4.e72","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"e72-e72","source":"Crossref","is-referenced-by-count":54,"title":["Impact of Protease Inhibitor-Containing Combination Antiretroviral Therapies on Height and Weight Growth in HIV-Infected Children"],"prefix":"10.1542","volume":"108","author":[{"given":"Kate","family":"Buchacz","sequence":"first","affiliation":[{"name":"From the Harvard School of Public Health, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Cervia","sequence":"additional","affiliation":[{"name":"Long Island Jewish Medical Center, New Hyde Park, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane C.","family":"Lindsey","sequence":"additional","affiliation":[{"name":"From the Harvard School of Public Health, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Hughes","sequence":"additional","affiliation":[{"name":"From the Harvard School of Public Health, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Seage","sequence":"additional","affiliation":[{"name":"From the Harvard School of Public Health, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne M.","family":"Dankner","sequence":"additional","affiliation":[{"name":"University of California San Diego, San Diego, California;"},{"name":"Parexel International Corporation, Durham, North Carolina;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Oleske","sequence":"additional","affiliation":[{"name":"University of Medicine and Dentistry of New Jersey, Newark, New Jersey; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Moye","sequence":"additional","affiliation":[{"name":"National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Pediatric AIDS Clinical Trials Group 219 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2001,10,1]]},"reference":[{"key":"2021120819154851000_B1","first-page":"685","article-title":"Weight, height and human immunodeficiency virus infection of young children of infected mothers.","volume":"14","author":"The European Collaborative Study","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"2021120819154851000_B2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-3476(96)70428-6","article-title":"for Women and Infants Transmission Study Group. Natural history of somatic growth in infants born to women infected with human immunodeficiency virus.","volume":"128","author":"Moye","year":"1996","journal-title":"J Pediatr"},{"key":"2021120819154851000_B3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0022-3476(05)80955-2","article-title":"Effect of human immunodeficiency virus infection on the growth of young children.","volume":"123","author":"McKinney","year":"1993","journal-title":"J Pediatr"},{"key":"2021120819154851000_B4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199104113241503","article-title":"A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease.","volume":"324","author":"McKinney","year":"1991","journal-title":"N Engl J Med"},{"key":"2021120819154851000_B5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00006454-200103000-00020","article-title":"Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children.","volume":"20","author":"Dreimane","year":"2001","journal-title":"Pediatr Infect Dis J"},{"key":"2021120819154851000_B6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1097\/00006454-199710000-00013","article-title":"Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors.","volume":"16","author":"Melvin","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"2021120819154851000_B7","first-page":"2356","article-title":"Ritonavir promotes increased growth in HIV-infected children.","volume":"12","author":"Nadal","year":"1998","journal-title":"AIDS"},{"key":"2021120819154851000_B8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1542\/peds.102.1.101","article-title":"A phase I\/II study of the protease inhibitor indinavir in children with HIV infection.","volume":"102","author":"Mueller","year":"1998","journal-title":"Pediatrics"},{"key":"2021120819154851000_B9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002030-199901140-00011","article-title":"Combination therapy including ritonavir in children infected with human immunodeficiency virus.","volume":"13","author":"Thuret","year":"1999","journal-title":"AIDS"},{"key":"2021120819154851000_B10","doi-asserted-by":"crossref","first-page":"158A","DOI":"10.1203\/00006450-199804001-00939","article-title":"Efficacy and tolerability of ritonavir in children with HIV infection: follow-up at one year [abstract 918].","volume":"43","author":"Sung","year":"1998","journal-title":"Pediatr Res"},{"key":"2021120819154851000_B11"},{"key":"2021120819154851000_B12","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199906033402207","article-title":"Treatments for wasting in patients with acquired immunodeficiency syndrome.","volume":"340","author":"Corcoran","year":"1999","journal-title":"N Engl J Med"},{"key":"2021120819154851000_B13"},{"key":"2021120819154851000_B14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/00006454-199611000-00018","article-title":"for the AIDS Clinical Trials Group Protocol 152 Study Team. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children.","volume":"15","author":"Englund","year":"1996","journal-title":"Pediatr Infect Dis J"},{"key":"2021120819154851000_B15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00002030-199811000-00019","article-title":"Pediatric AIDS prognosis using somatic growth velocity.","volume":"12","author":"Carey","year":"1998","journal-title":"AIDS"},{"key":"2021120819154851000_B16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0022-3476(06)80170-8","article-title":"Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine.","volume":"125","author":"McKinney","year":"1994","journal-title":"J Pediatr"},{"key":"2021120819154851000_B17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.284.2.190","article-title":"Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection.","volume":"284","author":"Martino","year":"2000","journal-title":"JAMA."},{"key":"2021120819154851000_B18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jama.283.4.492","article-title":"Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.","volume":"283","author":"Nachman","year":"2000","journal-title":"JAMA"},{"key":"2021120819154851000_B19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/ajcn\/46.5.736","article-title":"Development of normalized curves for the international growth reference: historical and technical considerations.","volume":"46","author":"Dibley","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"2021120819154851000_B20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ajcn\/46.5.749","article-title":"Interpretation of z-score anthropometric indicators derived from the international growth reference.","volume":"46","author":"Dibley","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"2021120819154851000_B21"},{"key":"2021120819154851000_B22","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","article-title":"Using the general linear mixed model to analyze unbalanced repeated measures and longitudinal data.","volume":"16","author":"Cnaan","year":"1997","journal-title":"Stat Med"},{"key":"2021120819154851000_B23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/00031305.1979.10482661","article-title":"Splines as a useful and convenient statistical tool.","volume":"33","author":"Smith","year":"1979","journal-title":"Am Statistician"},{"key":"2021120819154851000_B24"},{"key":"2021120819154851000_B25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less.","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"2021120819154851000_B26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"2021120819154851000_B27","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1089\/088922200414956","article-title":"Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial\u2014PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.","volume":"16","author":"Wiznia","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021120819154851000_B28","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med"},{"key":"2021120819154851000_B29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00126334-200003010-00004","article-title":"Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group.","volume":"23","author":"Bonfanti","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021120819154851000_B30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/aje\/152.10.923","article-title":"Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus.","volume":"152","author":"Ahdieh","year":"2000","journal-title":"Am J Epidemiol"},{"key":"2021120819154851000_B31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/00002030-199909100-00008","article-title":"Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.","volume":"13","author":"Funk","year":"1999","journal-title":"AIDS"},{"key":"2021120819154851000_B32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02560507","article-title":"Preliminary experiences with ritonavir in children with advanced HIV infection.","volume":"27","author":"Horneff","year":"1999","journal-title":"Infection"},{"key":"2021120819154851000_B33"},{"key":"2021120819154851000_B34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archpedi.1995.02170180027004","article-title":"Longitudinal assessment of growth in children born to mothers with human immunodeficiency virus infection.","volume":"149","author":"Saavedra","year":"1995","journal-title":"Arch Pediatr Adolesc Med"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/4\/e72\/895373\/pe10010000u1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/108\/4\/e72\/895373\/pe10010000u1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:34:55Z","timestamp":1734507295000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/108\/4\/e72\/67304\/Impact-of-Protease-Inhibitor-Containing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2001,10,1]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.108.4.e72","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10,1]]}}}